The latest medical news on Dermatology

The research magnet gathers the latest research from around the web, based on your specialty area. Below you will find a sample of some of the most recent articles from reputable medical journals about dermatology gathered by our medical AI research bot.

The selection below is filtered by medical specialty. Registered users get access to the Plexa Intelligent Filtering System that personalises your dashboard to display only content that is relevant to you.

Want more personalised results?

Request Access
MD Magaizine Derm

The US Food and Drug Administration has approved minocycline topical foam, 4% for the treatment of inflammatory lesions of non-nodular moderate to ...

Skincare Doc

The acronym BFF stands for “best friends forever,” a term used while instant messaging on the computer or sending a text message on cell phones. It...

MD Magaizine Derm

Results from the phase 3 IMMhance study show that of patients who reached sPGA 0 at week 28, 73% maintained skin clearance at week 94.

MD Magaizine Derm

Ixekizumab (Talz) was significantly more likely to both reduce disease activity by ≥50% and achieve complete skin clearance than adalimumab (Humira).

MD Magaizine Derm

Both brick-and-mortar dermatology clinics as well as telehealth programs are limited and restricted by barriers to access.

MD Magaizine Derm

After showing the ability to regain patients' senses of smell and taste in a pair of phase 3 trials, the biologic becomes the first indicated for C...

MD Magaizine Derm

A recent study examined the relationship between different types of infection and incidence of stroke. 

MD Magaizine Derm

After a decade-plus, the risk management reduction program is not associated with a direct drop in at-risk pregnancies.

MD Magaizine Derm

The selective inhibitor was previously approved to treat plaque psoriasis and psoriatic arthritis.

MD Magaizine Derm

A new cohort shows FLG loss-of-function variations are often different among AD pediatric patients with different ancestries.

MD Magaizine Derm

New phase 3 data will evidence an FDA application for the biologic as an add-on therapy for patients aged 6-11 years with AD.

MD Magaizine Derm

The epicutaneous immunotherapy patch BLA was previously submitted to the FDA last year, but withdrawn due to concerns over manufacturing procedure ...